Your session is about to expire
← Back to Search
Chemotherapy +/− Trastuzumab for Breast Cancer
Study Summary
This trial is comparing two different regimens of combination chemotherapy given together with or without trastuzumab to see how well they work in treating patients with stage II or stage III breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had cancer in the past 5 years, except for certain skin cancers or early-stage cervical cancer.I have inflammatory breast cancer.I had a non-spreading breast cancer diagnosis within the last 5 years.I haven't taken hormone therapy for conditions other than preventing breast cancer in the last 5 years.I have had radiation therapy to my chest before.I can do most of my daily activities without help.I am either male or female.My breast cancer is either ductal or lobular type.My condition is at stage II or III.I do not have significant nerve damage.
- Group 1: Docetaxel, Doxorubicin Hydrochloride, and Cyclophosphamide
- Group 2: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel and Carboplatin
- Group 3: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel, Carboplatin and trastuzumab
- Approved for 20 Other Conditions - This treatment demonstrated efficacy for 20 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Would I be a suitable candidate for participation in this medical experiment?
"To qualify for the trial, applicants must have breast cancer and be between 18-120 years old. 105 individuals are being sought to participate in the research."
What kind of adverse effects can be incurred from trastuzumab utilization?
"Trastuzumab has had some clinical trials to establish its safety, so it was given a score of 2. There is no current data showing efficacy for this drug yet."
What maladies can trastuzumab effectively ameliorate?
"Trastuzumab is a commonly prescribed drug for treating esophageal cancer, and it has also been used to address lymphoma, acute lymphoblastic leukemia, and various head-related ailments."
Are senior citizens able to partake in this clinical investigation?
"This clinical trial requires that participants are between 18 and 120 years of age. There is a total of 4835 trials for patients outside this range, including 416 dedicated to those under 18 and 4419 for seniors above 65."
Are there any vacant spots available for this study's participants?
"According to clinicaltrials.gov, this medical experiment is not actively recruiting participants at this moment in time. Upon first being posted on September 14th 2005 and last updated on January 5th 2021, the trial has since been closed off. Nonetheless, 4756 other trials are accepting applicants presently."
Does this trial represent a unique contribution to clinical research?
"According to the data available, there are 2153 active trials for trastuzumab situated within 86 countries and 4292 cities. The first of such experiments commenced in 1997 with Alfacell as its sponsor; this trial tested 300 participants during Phase 3 drug approval. Following that initial experiment 3607 more have been conducted since then."
Could you elucidate what the upper boundary of participants is for this clinical experiment?
"This trial is not presently taking in new patients, having been originally posted on September 14th 2005 and most recently updated on January 5th 2021. Alternatively, there are 2603 studies involving breast cancer and 2153 trials using trastuzumab that are actively accepting enrollees."
Could you please elucidate on the past investigations that have been conducted involving trastuzumab?
"At this time, there are 2153 ongoing clinical trials investigating trastuzumab with 537 studies in Phase 3. Although Seattle is an important site for these experiments, the drug's research network spans 102076 other locations."
Share this study with friends
Copy Link
Messenger